FDA reports more than 1,700 adverse events tied to compounded GLP-1 products

The U.S. Food and Drug Administration has disclosed that, as of May 21, 2026, it had received more than 1,700 adverse event reports associated with compounded semaglutide and tirzepatide ^[1]. The figure appears on an agency webpage laying out FDA's concerns with unapproved GLP-1 drugs used for weight loss, and it landed alongside a fresh round of enforcement aimed at telehealth companies that sell these products ^[1].

Compounded semaglutide and tirzepatide are not the same thing as Ozempic, Wegovy, Mounjaro or Zepbound. Compounded versions are mixed by pharmacies or outsourcing facilities rather than manufactured under an approved application. FDA's position is that these products "have not undergone the rigorous review for safety, efficacy, and manufacturing quality" required for drugs cleared through the new drug application or abbreviated new drug application pathways ^[1].

What FDA flagged

The adverse event count is one of several concerns listed on the agency's GLP-1 page. The others include import alerts meant to keep GLP-1 active pharmaceutical ingredients with quality problems out of the United States; FDA's position that retatrutide and cagrilintide may not be used in compounding; dosing concerns tied to GLP-1 products; and counterfeit versions of brand-name GLP-1 drugs circulating in the market ^[1].

During the week of June 15, 2026, FDA issued 25 warning letters to telehealth companies over allegedly false or misleading promotional claims about compounded GLP-1 products, which the agency treats as misbranding under the Federal Food, Drug, and Cosmetic Act ^[1]. That follows roughly 80 warning letters and 40 untitled letters in September 2025 and 30 warning letters in March 2026 ^[1]. Across 2025, FDA's Office of Prescription Drug Promotion issued 58 letters addressing claims about compounded GLP-1s and other compounded products such as sildenafil and tadalafil ^[1].

The marketing claims FDA is targeting are specific. They include describing a compounded product as a "generic" version of an approved GLP-1 drug; suggesting FDA approved or reviewed the compounded product; saying it is "clinically proven" to deliver the same results as the brand; claiming the product came from an "FDA-approved" or "FDA-licensed" pharmacy, which FDA says is misleading because it does not approve or license compounding facilities that way; and branding that makes a telehealth company look like the compounder when it is not ^[1]. FDA also objects to "exact same active ingredient" phrasing when it is used to imply sameness with the brand-name drug ^[1].

CDER Acting Director Michael Davis put the message plainly in a public post: "Patients deserve to know what they're getting — compounded GLP-1 products have not been proven safe, effective, or of consistent quality like FDA-approved drugs" ^[1].

Why it matters for patients

A raw count of adverse event reports is not the same as a rate. The source does not say how many people used compounded GLP-1 products over that period, what the reports described, how serious they were, or whether any were confirmed to be caused by the products ^[1]. Adverse event databases generally collect voluntary reports, and the specific reporting obligations that apply to different types of compounders are not spelled out in the material reviewed here, so how complete the 1,700-plus figure is remains unclear from this source.

What the disclosure does tell patients is that FDA is tracking harm reports tied to compounded versions separately from approved products, and that it views the marketing around them as a safety issue, not just a paperwork one. If a website describes a compounded GLP-1 as a generic, as FDA-approved, or as clinically proven to match the brand, those are the exact claims the agency has been sending warning letters about ^[1].

What happens next

FDA's enforcement has come in waves rather than a steady stream, and the law firm analyzing the letters notes that quiet stretches should not be read as reduced priority ^[1]. Recent leadership changes, including the May dismissal of Commissioner Dr. Marty Makary, do not appear to have altered the agency's course ^[1]. No date has been announced for the next batch of letters or for an updated adverse event count.